Liposome® forte


International nonproprietary name

No

Dosage form

Solution for injection, 28mg/2ml


Compound

2 ml of solution contain

active substance - hypothalamic phospholipids 28.0 mg,

excipients: mannitol, sodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, esters

p-hydroxybenzoic acid, water for injection.

Description

White to cream-colored opalescent solution with a characteristic odor.


Pharmacotherapeutic group

Drugs for the treatment of diseases of the nervous system.

Other psychostimulants and nootropics.

ATX code N06ВХ

Pharmacological properties

Pharmacokinetics

After administration of the drug parenterally, metabolic processes were studied both in terms of assessing total radioactivity
and at the cellular level. Research data shows that the molecules are stable in the blood and reach brain cells.

Pharmacodynamics

Parenteral administration of hypothalamic phospholipids can activate hypothalamic metabolism 
by increasing the turnover of dopamine, tyrosine hydroxylase and adenylate cyclase with subsequent accumulation 
of cyclic AMP. This pharmacological effect is reflected especially on the functions of the hypothalamic-pituitary system. 
By influencing the physicochemical properties of neuronal membranes, hypothalamic phospholipids alter
the adaptation of central neuron receptors to treatment.

Indications for use

An adjuvant in the treatment of metabolic cerebral disorders due to neuroendocrine disorders.

Directions for use and doses

Liposome® forte is administered 2 ml intramuscularly or intravenously

1 per day. The course of treatment is determined by the doctor individually.

Side effects

No adverse side effects were detected.

If side effects occur that are not listed in the instructions, you should consult a doctor.

- allergic reactions (skin itching, urticaria, rash)

Contraindications

- established hypersensitivity to the components of the drug

- presence of infection or damage to the skin in the area

injections

Drug interactions

Clinically significant interactions of the drug with other drugs have not been established. 
Liposome® forte can be administered simultaneously with other pharmaceutical products and, 
in particular, with antipsychotics, with drugs against hyperprolactinemia, with tricyclic
antidepressants (reduces the delay of action and increases efficiency) and with cardiac drugs.

Special instructions

The drug does not entail any special warnings or precautions for use.

Do not use the drug with damaged or opened packaging.

Use in pediatrics

The drug is not recommended for use in children due to the lack of data on the safety and effectiveness of use in pediatrics.

Pregnancy and lactation

During pregnancy and lactation (breastfeeding), the drug should be used under strict medical supervision.

Features of the effect of the drug on the ability to drive vehicles and potentially dangerous mechanisms

Liposome® forte does not affect a person’s ability to drive vehicles or engage in other
potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Overdose

No overdose symptoms were identified when treated with recommended doses.

In case of accidental overdose, treatment is symptomatic.

Release form and packaging

Injection solution for intramuscular or intravenous use.

2 ml in orange glass ampoules type I.

5 ampoules each in a blister pack made of polyvinyl chloride film.

1 blister pack together with instructions for medical use in the state and Russian languages ​​are placed in a cardboard box.

Storage conditions

Store at a temperature not exceeding 25°C.

Keep out of the reach of children!

Conditions for dispensing from pharmacies

On prescription


Manufacturer/Packager

Fidia Pharmaceutisi S.P.A.

35031, Abano Terme, Via Ponte della

Fabbrica, Z/A, Italy


Registration Certificate Holder

Fidia Pharmaceutisi S.P.A.

35031, Abano Terme, Via Ponte della

Fabbrica, Z/A, Italy